Summit Therapeutics (SMMT) Reports Q2 Loss of GBP0.07/Share
Summit Therapeutics (NASDAQ: SMMT) reported Q2 EPS of (GBP0.07), versus (GBP0.08) reported last year.
For earnings history and earnings-related data on Summit Therapeutics (SMMT) click here.